{"meta":{"totalResults":4,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Eligard"},{"type":"ForeignBrandName","name":"Luprodex Depot"},{"type":"Abbreviation","name":"LEUP"},{"type":"ObsoleteName","name":"Lupron"},{"type":"USBrandName","name":"Lupron Depot"},{"type":"ForeignBrandName","name":"Enantone"},{"type":"ChemicalStructureName","name":"6-D-leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing hormone-releasing factor (pig) monoacetate"},{"type":"ChemicalStructureName","name":"6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (pig) monoacetate"},{"type":"CodeName","name":"A-43818"},{"type":"CodeName","name":"Abbott 43818"},{"type":"LexicalVariant","name":"Abbott-43818"},{"type":"ForeignBrandName","name":"Carcinil"},{"type":"ForeignBrandName","name":"Enanton"},{"type":"ForeignBrandName","name":"Enantone-Gyn"},{"type":"ForeignBrandName","name":"Ginecrin"},{"type":"ForeignBrandName","name":"Leuplin"},{"type":"Synonym","name":"leuprorelin acetate"},{"type":"ForeignBrandName","name":"Lucrin Depot"},{"type":"ForeignBrandName","name":"Lucrin"},{"type":"ObsoleteName","name":"Lupron Depot-3 Month"},{"type":"ObsoleteName","name":"Lupron Depot-4 Month"},{"type":"ObsoleteName","name":"Lupron Depot-Ped"},{"type":"ForeignBrandName","name":"Procren"},{"type":"ForeignBrandName","name":"Procrin"},{"type":"ForeignBrandName","name":"Prostap"},{"type":"CodeName","name":"TAP-144"},{"type":"ForeignBrandName","name":"Trenantone"},{"type":"ForeignBrandName","name":"Uno-Enantone"},{"type":"ObsoleteName","name":"Viadur"},{"type":"ForeignBrandName","name":"Depo-Eligard"},{"type":"ForeignBrandName","name":"Lutrate"},{"type":"CASRegistryName","name":"74381-53-6"}],"definition":{"html":"The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","text":"The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/leuprolideacetate","text":"Leuprolide Acetate"},"nciConceptId":"C1319","nciConceptName":"Leuprolide Acetate","termId":40058,"name":"leuprolide acetate","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"leuprolide-acetate"},{"aliases":[{"type":"CodeName","name":"TOL 2506"},{"type":"CodeName","name":"TOL2506"},{"type":"CodeName","name":"TOL-2506"}],"definition":{"html":"A subcutaneous injectable suspension formulation containing the acetate salt form of leuprolide, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous administration of the leuprolide acetate for injectable suspension TOL2506, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. In females, this decreases estradiol production and level, suppresses ovarian function and may inhibit proliferation of estrogen receptor (ER)-positive breast cancer.","text":"A subcutaneous injectable suspension formulation containing the acetate salt form of leuprolide, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous administration of the leuprolide acetate for injectable suspension TOL2506, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. In females, this decreases estradiol production and level, suppresses ovarian function and may inhibit proliferation of estrogen receptor (ER)-positive breast cancer."},"drugInfoSummaryLink":null,"nciConceptId":"C185872","nciConceptName":"Leuprolide Acetate for Injectable Suspension TOL2506","termId":809601,"name":"leuprolide acetate for injectable suspension TOL2506","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"leuprolide-acetate-for-injectable-suspension-tol2506"},{"aliases":[{"type":"CASRegistryName","name":"SR PT105"},{"type":"Synonym","name":"leuprorelin acetate sustained-release microspheres PT105"},{"type":"CodeName","name":"PT105"},{"type":"CodeName","name":"PT-105"},{"type":"CodeName","name":"PT 105"}],"definition":{"html":"A sustained-release (SR) injectable microsphere formulation composed of the acetate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In females, prolonged administration results in a decrease in estradiol production and suppression of ovarian function. Leuprolide also reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","text":"A sustained-release (SR) injectable microsphere formulation composed of the acetate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In females, prolonged administration results in a decrease in estradiol production and suppression of ovarian function. Leuprolide also reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression."},"drugInfoSummaryLink":null,"nciConceptId":"C179722","nciConceptName":"Leuprolide Acetate Sustained-release Microspheres PT105","termId":805086,"name":"leuprolide acetate sustained-release microspheres PT105","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"leuprolide-acetate-sustained-release-microspheres-pt105"},{"aliases":[{"type":"USBrandName","name":"Camcevi"},{"type":"CASRegistryName","name":"944347-41-5"}],"definition":{"html":"The mesylate salt form of leuprolide, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","text":"The mesylate salt form of leuprolide, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/leuprolide-mesylate","text":"Leuprolide Mesylate"},"nciConceptId":"C190727","nciConceptName":"Leuprolide Mesylate","termId":764623,"name":"leuprolide mesylate","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"leuprolide-mesylate"}],"links":null}